It was further shown that vascular endothelial growth factor C (VEGF-C) treatment potentiated immunotherapies against amyloid beta, leading to better outcomes in mouse models of Alzheimer’s disease, elucidating the important roles that the meningeal lymphatic system may play in neurological disease [29]. This evidence concerns the gene VEGFC and early-onset autosomal dominant Alzheimer disease.